World Vaccines Market 2013-2023

  • October 2013
  • -
  • Visiongain
  • -
  • 190 pages

Report Details

Vaccines and their technology - your guide to developments, opportunities, and revenues

See what the future holds for vaccines. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product, and national level to 2023.

Make sure you understand trends, R&D, opportunities, and prospects there, in human medicine, helping your research, analyses, and decisions. Discover in our work what's likely to happen for those technologies. You find there how you can benefit.

Read on to explore that industry and see what its future market could be worth.

Forecasts from 2013-2023 and other analyses show you commercial prospects

Besides revenue forecasting to 2023, our new study gives you historical data, recent results, growth rates, and market shares. There you find original analysis, with business outlooks and developments (R&D). You also get two interviews, 50 charts, and 91 tables.

Gains through understanding the vaccines sector - find advantages for your work

Leaders hold knowledge. So hear what's happening for development, production, and sales of those preventative medicines. There you see where needs and money exist, from 2013, finding how you and your organisation can prosper.

Use our predictions for vaccination, then, to help expand your business and give you more influence. Avoid falling behind there - try our new report.

So the following sections reveal what you get in that new investigation.

Revenues for the world vaccines market and submarkets

What're the secrets of that industry's progress? What's its potential? Discover in our report overall world revenue to 2023. Also find individual forecasts for four submarkets at world level:
• Paediatric products
• Influenza treatments
• Adult prophylactic agents
• Therapeutic vaccines.

How will sales rise? See, then, which product classes can generate most revenue. There you assess prospects for commercial expansion. Discover now the money-earning potential.

Explore the market for vaccinations by brand too.

Forecasts and discussions for leading products

How will leading brands perform to 2023 at world level? Our work shows you 10 individual revenue forecasts to 2023 for top products:
• Prevnar
• Pentacel, Pediacel, and Pentaxim
• ProQuad, M-M-R II, and Varivax
• RotaTeq
• Fluzone, Panenza, Humenza, Intanza, IDflu, and Emerflu.

And also for these:
• Gardasil
• Infanrix and Pediarix
• Engerix, Fendrix, Havrix, Twinrix, and Ambirix
• Menactra and other vaccines for meningitis and pneumonia
• Zostavax.

There you assess those agents, seeing activities, results and outlooks. You discover what's happening, understanding trends, competition, and sales prospects. Assess the future.

Our study also divides its overarching forecast into geographical regions.

Healthcare in national markets - what're the outlooks for vaccine sales?

Progress worldwide in medicine and healthcare will expand vaccination. You hear about the best revenue prospects for those preventative medicines, getting feel for national prospects.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC).

There you assess developed and developing countries for revenues and potential sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Research and development - explore trends, possibilities, and innovations

You also investigate R&D for immune system modifiers, finding possibilities for technological and commercial advances.

In particular, our report discusses these medical technologies:
• Paediatric agents - protecting

Table Of Contents

1. Executive Summary

1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
1.4 What Are Vaccines?

2. Overview of Vaccines Market, 2013-2023

2.1 Vaccines Market to Continue to Perform Strongly to 2023
2.2 Paediatric Vaccines Remain Central to Market
2.2.1 Adult Vaccination and Therapeutic Vaccines the Major Drivers to 2023
2.3 What Diseases and Technologies Drive the Market in 2013?
2.3.1 Ancillary Technologies
2.4 Pfizer's Prevnar Leads the Market in 2013
2.5 Top Three Companies Held 52% of Market in 2012
2.5.1 Sanofi Pasteur: Leading Paediatric Portfolio
2.5.2 GlaxoSmithKline: a Strong Presence in Every Segment
2.5.3 Merck: Zostavax Revival Boosts 2012 Performance
2.5.4 Pfizer: A Major Player on the Strength of Prevnar
2.5.5 Novartis: Vaccines Business to be Divested?
2.5.6 Other Players in the Market: A Crowded Second Tier

3. Paediatric Vaccines Segment, 2013-2023

3.1 Segment to Lose Market Share, but Still Record Strong Growth
3.2 Combinations Form Basis of Segment Revenues
3.3 Prevnar Franchise Represents a Quarter of the Paediatric Segment's Total Value in 2012
3.3.1 Prevnar-13: Domination to Continue?
3.3.1.1 First of the Blockbuster Vaccines
3.3.1.2 Label Extensions for Prevnar Continue
3.3.1.3 Synflorix Competing Strongly in Emerging Markets
3.3.1.4 Big Three Vaccine Manufacturers All Set to Challenge Pfizer in Pneumococcal Disease Area
3.3.1.5 How Much Room for Growth for Prevnar-13?
3.3.2 Sanofi Pasteur and GlaxoSmithKline Competing in Paediatric Combination Space
3.3.2.1 Hexaxim Boosts Sanofi Portfolio
3.3.2.2 GlaxoSmithKline Combinations Make Gains in US in 2012
3.3.2.3 Inadequacies in Pertussis and Hepatitis B Care
3.3.2.4 Room for Vaccine Competition in Those Disease Areas?
3.3.2.5 Sanofi and GSK Head-to-Head, 2013-2023
3.3.3 Competition Increases in Meningitis Vaccines Space
3.3.3.1 Menveo Label Widened in August 2013
3.3.3.2 Other Competitors for Paediatric A, C, Y and W-135 Serotypes Market
3.3.3.3 Bexsero Still to Convince EU Payers
3.3.4 Four-Disease Combination is Merck's Leading Paediatric Vaccine
3.3.4.1 Supply Issues Still Restraining ProQuad
3.3.4.2 Varivax Commercial Backbone of Combination
3.3.4.3 Mumps Immunity Waning?
3.3.4.4 Will MMR-II/ProQuad/Varivax Realise its Full Market Potential?
3.3.5 Duel for the Rotavirus Market Continues
3.3.5.1 RotaTeq Leads the Market
3.3.5.2 Rotavirus Immunisation Added to UK Schedules
3.3.5.3 New Chinese and Indian Products Come to Developing World
3.3.5.4 Will RotaTeq Hit the Blockbuster Heights?
3.3.6 Paediatric Vaccines Against Other Diseases, 2013
3.3.6.1 Japanese Encephalitis Vaccine Approved for Children
3.3.6.2 Mosquirix Records Disappointing Phase 3 Data
3.3.6.3 Sanofi Records a First in 50 Years of Dengue Research
3.3.6.4 Two MedImmune RSV Vaccines in Development
3.3.6.5 Novartis Targeting Typhoid Opportunity
3.3.6.6 Hand, Foot and Mouth Vaccine: A Chinese Target
3.3.6.7 Anthrax Vaccines for Children?
3.3.6.8 Potential Vaccines for Autism and Diabetes
3.4 Summary: The Biggest Segment, but the Least Dynamic

4. Influenza Vaccines Segment, 2013-2023

4.1 New Pandemics Offer Biggest Growth Opportunities to 2023
4.2 Major Seasonal and Pandemic Vaccine Opportunities Remain
4.3 Abbvie and AstraZeneca Among the Segment's Big Players
4.3.1 Sanofi has the Largest Influenza Franchise
4.3.1.1 Seasonal Vaccines Dominate the Franchise
4.3.1.2 Quadrivalent Product Will Bolster Steady Growth for the Fluzone-Led Franchise
4.3.1.3 Novartis' Portfolio Leads the Seasonal Influenza Competition
4.3.1.4 GlaxoSmithKline and AstraZeneca Also Competing
4.3.1.5 Merck to Join the Seasonal Market Leaders?
4.3.2 Differentiating Seasonal Influenza Vaccines
4.3.2.1 CDC Promises Redesign of Influenz

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.